GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Weekly CEO Buys Highlight: UTHR, TAT, PMC, BRCD, ENDP

June 16, 2012 | About:
GuruFocus

gurufocus

360 followers
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below:



Utd Therapeutic (UTHR): CEO Martine A Rothblatt Bought 31,368 Shares

CEO of Utd Therapeutic (UTHR) Martine A Rothblatt bought 31,368 shares during the past week at an average price of $47.78. UTD THERAPEUTIC is a biotechnology company focused on combating cardiovascular, inflammatory, and infectious diseases with unique therapeutic products. Utd Therapeutic has a market cap of $2.32 billion; its shares were traded at around $47.78 with a P/E ratio of 9.8 and P/S ratio of 3.1.

Total revenues for the quarter ended March 31, 2012 were $204.2 million, up from $162.5 million for the quarter ended March 31, 2011. Net income for the quarter ended March 31, 2012 was $70.8 million or $1.32 per basic share, compared to $16.4 million or $0.28 per basic share for the same quarter in 2011. Gross margin from sales was $178.9 million for the quarter ended March 31, 2012, compared to $142.5 million for the same quarter last year. Earnings before non-cash charges(1) for the quarter ended March 31, 2012 were $114.4 million, compared to $80.7 million for the quarter ended March 31, 2011.

Richard Perry bought 15,300 shares in the quarter that ended on 03/31/2012, which is 0.035% of the $2.08 billion portfolio of Perry Capital. Joel Greenblatt owns 165,063 shares as of 03/31/2012, an increase of 82.68% from the previous quarter. This position accounts for 0.68% of the $1.15 billion portfolio of Gotham Capital. Edward Owens owns 1,787,000 shares as of 03/31/2012, which accounts for 0.4% of the $20.91 billion portfolio of Vanguard Health Care Fund.

Director Christopher Patusky sold 2,500 shares of UTHR stock on 04/04/2012 at the average price of 45.55. Christopher Patusky owns at least 1,300 shares after this. The price of the stock has increased by 4.9% since. Other insiders have also decreased their positions in the company.

Transatl Petrol (TAT): CEO, 10% Owner Noah Malone Mitchell Iii Bought 456,394 Shares

CEO, 10% Owner of Transatl Petrol (TAT) Noah Malone Mitchell Iii bought 456,394 shares during the past week at an average price of $0.99. TransAtlantic Petroleum Ltd. is a vertically integrated, international oil and gas company. Transatl Petrol has a market cap of $358.8 million; its shares were traded at around $0.99 with and P/S ratio of 2.8.

Transatlantic Petrol recently reported its second quarter 2012 results. The company reported revenues of $1.2 billion, compared with $1.1 billion for the second quarter of 2011. Net loss was $13.2 million, compared with $8.7 million in 2011.

COO Mustafa Yavuz bought 7,409 shares of TAT stock on 06/12/2012 at the average price of 1. Mustafa Yavuz owns at least 7,409 shares after this.

Pharmerica Corp (PMC): CEO Gregory S Weishar Bought 35,500 Shares

CEO of Pharmerica Corp (PMC) Gregory S Weishar bought 35,500 shares on 06/14/2012 at an average price of $10.18. PharMerica Corporation is an institutional pharmacy services provider dedicated to providing quality customer service and innovative pharmacy solutions to institutional customers and patients in long-term care settings. Pharmerica Corp has a market cap of $287.9 million; its shares were traded at around $10.18 with a P/E ratio of 7.3 and P/S ratio of 0.1. Pharmerica Corp had an annual average earnings growth of 18.6% over the past 5 years.

Phamerica recently reported its first quarter 2012 financial results. Revenues were $498.9 million, compared to $535.1 million in the first quarter of 2011. Gross profit for the first quarter 2012 was $72.6 million, compared to $66.1 million in the first quarter of 2011.

HOTCHKIS & WILEY owns 768,800 shares as of 03/31/2012, which accounts for 0.057% of the $16.79 billion portfolio of Hotchkis & Wiley Capital Management LLC. Jean-Marie Eveillard sold out his holdings in the quarter that ended on 03/31/2012.

EVP and CFO Michael J Culotta bought 15,000 shares of PMC stock on 06/14/2012 at the average price of 9.51. Michael J Culotta owns at least 158,208 shares after this. The price of the stock has increased by 7.05% since. Other insiders have also increased their positions in the company.

Brocade Comm Sy (BRCD): CEO Michael Klayko Bought 60,000 Shares

CEO of Brocade Comm Sy (BRCD) Michael Klayko bought 60,000 shares on 06/13/2012 at an average price of $4.79. Brocade Communications Systems, Inc. delivers industry-platforms, solutions, and services for intelligently connecting, managing, and optimizing IT resources in shared storage environments. Brocade Comm Sy has a market cap of $2.14 billion; its shares were traded at around $4.79 with a P/E ratio of 12.6 and P/S ratio of 1. Brocade Comm Sy had an annual average earnings growth of 15.3% over the past 10 years. GuruFocus rated Brocade Comm Sy the business predictability rank of 2-star.

BRCD recently reported financial results for its second fiscal quarter ended April 28, 2012. Brocade reported second quarter revenue of $543.4 million, representing a decrease of 1% year-over-year and 3% quarter-over-quarter and resulting in diluted earnings per share of $0.08 on a GAAP basis and diluted earnings per share of $0.15 on a non-GAAP basis, up 58% and 24% year-over-year, respectively.

David Dreman bought 4,141,969 shares in the quarter that ended on 03/31/2012, which is 0.5% of the $4.79 billion portfolio of Dreman Value Management. Ray Dalio owns 543,135 shares as of 03/31/2012, an increase of 1579.71% from the previous quarter. This position accounts for 0.049% of the $6.43 billion portfolio of Bridgewater Associates. Joel Greenblatt owns 243,087 shares as of 03/31/2012, an increase of 123.38% from the previous quarter. This position accounts for 0.12% of the $1.15 billion portfolio of Gotham Capital.

CFO, VP of Finance Daniel W Fairfax sold 20,378 shares of BRCD stock on 03/23/2012 at the average price of 5.65. Daniel W Fairfax owns at least 218,123 shares after this. The price of the stock has decreased by 15.22% since. Other insiders have also decreased their positions in the company.

Endo Pharmaceut (ENDP): President & CEO David Holveck Bought 8,550 Shares

President & CEO of Endo Pharmaceut (ENDP) David Holveck bought 8,550 shares on 06/12/2012 at an average price of $30.13. Endo Pharmaceuticals Holdings Inc., through its wholly owned subsidiaries, Endo Pharmaceuticals Inc. Endo Pharmaceut has a market cap of $3.5 billion; its shares were traded at around $30.13 with a P/E ratio of 6.5 and P/S ratio of 1.3. Endo Pharmaceut had an annual average earnings growth of 31.7% over the past 10 years. GuruFocus rated Endo Pharmaceut the business predictability rank of 3.5-star.

Joel Greenblatt bought 17,025 shares in the quarter that ended on 03/31/2012, which is 0.057% of the $1.15 billion portfolio of Gotham Capital. Lee Ainslie owns 5,508,833 shares as of 03/31/2012, an increase of 86.23% from the previous quarter. This position accounts for 3.1% of the $6.95 billion portfolio of Maverick Capital. David Dreman owns 92,625 shares as of 03/31/2012, which accounts for 0.075% of the $4.79 billion portfolio of Dreman Value Management. John Hussman owns 1,914,000 shares as of 03/31/2012, which accounts for 1.4% of the $5.16 billion portfolio of Hussman Economtrics Advisors.


Rating: 3.0/5 (7 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK